APOE PRS | Non-APOE PRS | |||||||
---|---|---|---|---|---|---|---|---|
Total sample (n = 818) | ||||||||
PRS version | β | SE | 95% CI | p | β | SE | 95% CI | p |
34-SNP PRS | 0.19 | 0.02 | 0.14–0.23 | 2e−17 | 0.06 | 0.02 | 0.02–0.10 | 2e−3 |
5e−8 PRS | 0.19 | 0.02 | 0.15–0.23 | 3e−18 | 0.08 | 0.02 | 0.03–0.12 | 3e−4 |
1e−5 PRS | 0.18 | 0.02 | 0.13–0.22 | 8e−16 | 0.05 | 0.02 | 0.004–0.09 | 0.03 |
PHS* | 0.18 | 0.02 | 0.13–0.22 | 7e−15 | 0.11 | 0.04 | 0.03–0.18 | 8e−3 |
Cogn unimpaired (n = 236) | ||||||||
β | SE | 95% CI | p | β | SE | 95% CI | p | |
34-SNP PRS | 0.16 | 0.05 | 0.05–0.27 | 3e−3 | 0.02 | 0.04 | − 0.07 to 0.10 | 0.7 |
5e−8 PRS | 0.20 | 0.05 | 0.09–0.31 | 3e−4 | 0.08 | 0.04 | − 0.003 to 0.17 | 0.06 |
1e−5 PRS | 0.18 | 0.06 | 0.07–0.28 | 2e−3 | 0.04 | 0.05 | − 0.05 to 0.13 | 0.4 |
PHS* | 0.19 | 0.06 | 0.08–0.30 | 1e−3 | 0.13 | 0.10 | − 0.08 to 0.33 | 0.2 |
MCI (n = 434) | ||||||||
β | SE | 95% CI | p | β | SE | 95% CI | p | |
34-SNP PRS | 0.21 | 0.03 | 0.15–0.27 | 8e−13 | 0.09 | 0.03 | 0.04–0.15 | 1e−3 |
5e−8 PRS | 0.21 | 0.03 | 0.15–0.26 | 2e−12 | 0.08 | 0.03 | 0.03–0.14 | 1e−4 |
1e−5 PRS | 0.19 | 0.03 | 0.14–0.25 | 4e−11 | 0.06 | 0.03 | 0.004–0.12 | 0.04 |
PHS* | 0.18 | 0.03 | 0.13–0.24 | 2e−9 | 0.11 | 0.06 | 0.004–0.22 | 0.04 |
AD (n = 148) | ||||||||
β | SE | 95% CI | p | β | SE | 95% CI | p | |
34-SNP PRS | 0.13 | 0.03 | 0.07–0.19 | 6e−5 | 0.03 | 0.03 | − 0.03 to 0.09 | 0.4 |
5e−8 PRS | 0.12 | 0.03 | 0.06–0.18 | 7e−5 | 0.03 | 0.03 | − 0.04 to 0.09 | 0.4 |
1e−5 PRS | 0.13 | 0.03 | 0.07–0.19 | 7e−5 | 0.03 | 0.03 | − 0.04 to 0.09 | 0.4 |
PHS* | 0.12 | 0.03 | 0.06–0.18 | 1e−4 | 0.06 | 0.05 | − 0.04 to 0.15 | 0.2 |